NeoPhore Ltd

NeoPhore, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Generation of cancer neoantigens in tumours can be exploited by the patients immune system to overcome natural defence mechanisms in cancer. The Companys approach targets the DNA mismatch repair (MMR) pathway, which has been proven to promote neoantigen creation and subsequent immunity against numerous cancers. Using these insights, NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore was spun-out of the University of Turin and PhoreMost Ltd by the CRT Pioneer...

Biotechnology,drug discovery,small molecule therapeutics,oncology,immuno-oncology,cancer,genetics,and translational medicine

Neophore ltd operates in the Biotechnology research industry.

Neophore ltd's revenue is 1m - 10m

Neophore ltd has 11 - 50 employees.